Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department.

Drug survival in a real-life setting is critical to long-term use of biologics for psoriasis. : We describe our 12-year experience with biologics in psoriasis patients. All patients treated with biologics including infliximab, adalimumab (ADA), etanercept (ETA), and ustekinumab (UST) for psoriasis vulgaris between January 2005 and December 2016 were retrospectively analyzed.

Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.

Introduction: Although the efficacy of TNF blockers has been demonstrated in hidradenitis suppurativa (HS), many paradoxical effects have also been described with TNF antagonists. We wished to describe patients with adalimumab (ADA)-induced paradoxical HS.

Methods: This is a retrospective descriptive case series of four patients with ADA-induced paradoxical HS.